Business Wire

Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research

Del

Regulatory News:

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that its neurotoxin portfolio will be the subject of 13 abstracts at the 12th International Society of Physical and Rehabilitation Medicine World Congress. The meeting will be held in Paris, July 8-12, 2018.

The 13 abstracts will present neuroscience data that advances knowledge in physical and rehabilitation medicine including clinical outcomes linked to Ipsen’s portfolio in adult spasticity (upper and lower limbs), pediatric spasticity, and in cervical dystonia. In addition, an international survey investigating the burden of spasticity on patients and their caregivers will be presented, as well as real-world data that supports better understanding of current clinical practices.

Alexandre Lebeaut, MD, Executive Vice-President, R&D, Chief Scientific Officer, Ipsen said: “Ipsen will have its strongest ever neuroscience presence at ISPRM 2018, demonstrating our strong focus on advancing the boundaries of neurotoxin research and our long-term commitment to patients and the neuroscience community, notably through medical education programs and symposia. We will also disclose new data from the first-ever recombinant botulinum neurotoxin to be administered to humans, an area where we have the ambition to advance and unlock the potential of this innovative technology platform.”

Prof. Lynne Turner-Stokes, [Cicely Saunders Institute, King’s College London, UK] added: “The results of the large observational ULIS-III study, which aims to assess real-life clinical practice will be the subject of an oral presentation. This study demonstrated that pain reduction is an important and achievable primary treatment goal in some patients suffering with spasticity.”

Oral presentations:

  • Abstract ISPR8-2524 – FP16 Neuro-Orthopedics and Spasticity - Part II, Amphitheatre Bleu Wednesday 11th July 17.40 – 17.50
    • Botulinum Toxin A in Upper Limb Spasticity Management: Baseline Data from the Upper Limb International Spasticity (ULIS)-III Study
    • Presenting author: Lynne Turner-Stokes
  • Abstract ISPR8-2530 – FP16 Neuro-Orthopedics and Spasticity - Part II, Amphitheatre Bleu Wednesday 11th July 17.50 – 18.00
    • Relief of Spasticity-Related Pain with Botulinum Neurotoxin-A (BoNT-A) in Real Life Practice. Post-Hoc Analysis from a Large International Cohort Series
    • Presenting author: Lynne Turner-Stokes

Posters

  • Abstract ISPR8-1217 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Impact of Spasticity and Botulinum Toxin-A Injections on the Daily Life of Patients and their Caregivers: Results from an International Online Survey
    • Presenting author: Manuel Murie Fernandez
  • Abstract ISPR8-2146 – D3.03 Education and Training in Rehabilitation – Continuous Medical Education and Professional Development, Exhibition Area, 9th–12th July
    • Botulinum Neurotoxin-A Usage and Training in Cervical Dystonia & Spastic Paresis: First Results from the Ixcellence® Network Survey
    • Presenting author: Luis Jorge Jacinto
  • Abstract ISPR8-2147 – D3.03 Education and Training in Rehabilitation – Continuous Medical Education and Professional Development, Exhibition Area, 9th–12th July
    • Improving Management Practices of Cervical Dystonia and Spastic Paresis: 5 Years’ Experience of Ixcellence® Network, an Innovative International Educational Program
    • Presenting author: Luis Jorge Jacinto
  • Abstract ISPR8-2514 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Simultaneous Upper and Lower Limb AbobotulinumtoxinA Injections and Guided Self-Rehabilitation Contracts in Spastic Hemiparesis: Baseline Data from the ENGAGE Study
    • Presenting author: Jean-Michel Gracies
  • Abstract ISPR8-2521 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Repeated AbobotulinumtoxinA Injections Benefit Walking Speed, Step Length and Cadence in Adults with Spastic Hemiparesis due to Stroke or Traumatic Brain Injury
    • Presenting author: Alberto Esquenazi
  • Abstract ISPR8-2529 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Efficacy and Safety of Early Use of AbobotulinumtoxinA in Adults with Post-Stroke Spasticity: Results from the ONTIME and ABCDE-S Studies
    • Presenting author: Raymond Rosales
  • Abstract ISPR8-2543 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Upper Limb Spasticity Following Stroke or Traumatic Brain Injury
    • Presenting author: Jean-Michel Gracies
  • Abstract ISPR8-2546 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • When Can Maximal Efficacy be Expected with Repeated Botulinum Toxin Injections in Upper Limb Spastic Paresis? An Exploratory Statistical Analysis
    • Presenting author: Jean-Michel Gracies
  • Abstract ISPR8-2547 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • AbobotulinumtoxinA Injections in Shoulder Muscles: Results from a Real World (ULIS-II) and Phase 3 (AUL) Studies
    • Presenting author: Francois Constant Boyer
  • Abstract ISPR8-2557 – A7.02 Rehabilitation Addressing to Specific Issues – Spasticity Management, Exhibition Area, 9th–12th July
    • Treatment Frequency for Long-Term Efficacy of AbobotulinumtoxinA Injections: a Phase 3 Study in Patients with Lower Limb Spasticity Following Stroke or Traumatic Brain Injury
    • Presenting author: Prof Jean-Michel Gracies
  • Abstract ISPR8-2654 – A2.08 Musculoskeletal Conditions – Miscellanous, Exhibition Area, 9th–12th July
    • Results from the First Recombinant Botulinum Toxin (BoNT) Ever to Enter Clinical Development. Outcomes of a First-in-Human Study with Recombinant BoNT/E (SXN102308)
    • Presenting author: Laurent Pons

About Dysport®

Dysport® is an injectable form of a botulinum neurotoxin type A product, which is a substance derived from Clostridium bacteria producing BoNT-A that inhibits the effective transmission of nerve impulses and thereby reduces muscular contractions. It is supplied as a lyophilized powder. As of 31 December 2017, Dysport® had marketing authorization in more than 85 countries.

About Spasticity

Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness in one or more muscles, which might interfere with movement. Spasticity is usually caused by damage to nerve pathways in the brain or spinal cord that control muscle movement, and may occur in association with cerebral palsy, spinal cord injury, multiple sclerosis, stroke, and brain or head trauma.3 In adults, approximately one in three stroke patients, one in three patients with spinal cord injury, one in six patients with traumatic brain injury, and two in three patients with MS will develop lower limb spasticity.1,2

INDICATIONS AND IMPORTANT SAFETY INFORMATION

Dysport® is approved for the treatment of adult upper and lower limb spasticity, pediatric lower limb spasticity and cervical dystonia (referred to spasmodic torticollis in some markets) in many international markets including France and the United States of America. Please refer to national labelling for details of the locally approved prescribing information in each of these indications.

Adverse effects resulting from the distribution of the effects of the toxin to sites remote from the site of administration have been reported. Patients treated with therapeutic doses may present with excessive muscle weakness. The risk of occurrence of such undesirable effects may be reduced by using the lowest effective dose possible and by not exceeding the maximum recommended dose.

Very rare cases of death, occasionally in the context of dysphagia, pneumopathy (including but not limited to dyspnoea, respiratory failure, respiratory arrest) and/or in patients with significant asthenia have been reported following treatment with botulinum toxin A or B. Patients with disorders resulting in defective neuromuscular transmission, difficulty in swallowing or breathing are more at risk of experiencing these effects. In these patients, treatment must be administered under the control of a specialist and only if the benefit of treatment outweighs the risk. Dysport® should be administered with caution to patients with pre-existing swallowing or breathing problems as these can worsen following the distribution of the effect of toxin into the relevant muscles. Aspiration has occurred in rare cases and is a risk when treating patients who have a chronic respiratory disorder. Dysport® should only be used with caution and under close medical supervision in patients with clinical or sub-clinical evidence of marked defective neuro-muscular transmission (e.g. myasthenia gravis). Such patients may have an increased sensitivity to agents such as Dysport®, which may result in excessive muscle weakness. Caution should be exercised when treating adult patients, especially the elderly, with focal spasticity affecting the lower limbs, who may be at increased risk of fall. In placebo-controlled clinical studies where patients were treated for lower limb spasticity, 6.3% and 3.7% of patients experienced a fall in the Dysport® and placebo groups, respectively. The recommended posology and frequency of administration for Dysport® must not be exceeded. Patients and their care-givers must be warned of the necessity to seek immediate medical treatment in case of problems with swallowing, speech or respiratory problems. For the treatment of spasticity in children, Dysport® should only be used in children 2 years of age or over. As with any intramuscular injection, Dysport® should only be used where strictly necessary in patients with prolonged bleeding times, or infection/inflammation at the proposed site(s) of injection. Dysport® should only be used to treat a single patient, during a single session. Any unused product remaining should be disposed of in accordance with Special Precautions for Disposal and Handling. Specific precautions must be taken during the preparation and administration of the product and the inactivation and disposal of any unused reconstituted solution. This product contains a small amount of human albumin. The risk of transmission of viral infection cannot be excluded with absolute certainty following the use of human blood or blood products.”

References:
1. Martin A, et al. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatric Disease and Treatment. 2014; 10 (111-122)
2. Sköld A, et al. Spasticity after traumatic spinal cord injury: nature, severity, and location. Archives of Physical Medicine and Rehabilitation. 1999; 80 (1548-57)
3. National Institute of Neurological Disorders and Stroke. Spasticity Information Page. https://www.ninds.nih.gov/Disorders/All-Disorders/Spasticity-Information-Page Accessed May 16, 2017.

About Ipsen

Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. Its commitment to Oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €1.9 billion in 2017, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,400 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2017 Registration Document available on its website (www.ipsen.com).

Contact information

For further information :
Ipsen
Media
Ian Weatherhead, +44 (0) 1753 627733
Vice President, Corporate External Communications
ian.weatherhead@ipsen.com
or
Brigitte Le Guennec, +33 (0)1 58 33 51 17
Senior Manager, Global External Communications
brigitte.le.guennec@ipsen.com
or
Financial Community
Eugenia Litz, +44 (0) 1753 627721
Vice President, Investor Relations
eugenia.litz@ipsen.com
or
Myriam Koutchinsky, +33 (0)1 58 33 51 04
Investor Relations Manager
myriam.koutchinsky@ipsen.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Process Systems Enterprise: gPROMS FormulatedProducts 1.4 Includes Enhanced Capabilities Linking Digital Design to Digital Operations19.4.2019 07:58:00 CESTPressemelding

Process Systems Enterprise (PSE), the Advanced Process Modelling company, today released version 1.4 of gPROMS FormulatedProducts, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation. This release introduces major enhancements to both the gPROMS FormulatedProducts model libraries and the underlying gPROMS platform 6.0, including morphological crystallizer and sensor models to capture particle size and shape evolution, enhanced continuous direct compression models and improved wet granulation models. Platform enhancements include support for cluster computing, to significantly speed up execution of parameter estimation and other complex numerical solutions, and comprehensive global system analysis of dynamic systems for rapid exploration of the time-varying decision space and systematic risk and uncertainty analysis. Version 1.4 also introduces two key usability enhan

LOXAM Contributes to the Reconstruction of Notre Dame De Paris Cathedral19.4.2019 07:44:00 CESTPressemelding

In the wake of the Notre Dame de Paris blaze on Monday 15 April, Loxam the leading equipment rental company in Europe is playing its part in the reconstruction project of the partly destroyed cathedral. A rental operator in the construction equipment, LOXAM pledges to provide, free of charge, machines to the companies and tradesmen who will take part in these restoration works for the scheduled duration of five years. “Notre Dame de Paris Cathedral is the legacy of accomplished builders that we ought to preserve. As a committed rental operator, Loxam wishes to contribute to the rehabilitation of this monument by providing equipment for an overall 10-million € value over the upcoming five years” Gérard DEPREZ, President of LOXAM, indicates. With a fleet of over 200,000 machines, Loxam is meeting the needs of all tradesmen operating on this worksite. View source version on businesswire.com: https://www.businesswire.com/news/home/20190419005025/en/ Contact information PRESS : Virginie Ada

IFF to Release First Quarter 2019 Results May 618.4.2019 20:15:00 CESTPressemelding

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of scent, taste, and nutrition, announced that it will release its first quarter 2019 earnings results following the market close on Monday, May 6, 2019. The management team will host a live webcast on Tuesday, May 7, 2019 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF) is a leading innovator of scent, taste, and nutrition, with 97 manufacturing facilities, 105 R&D centers, and 39,000 customers globally. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration dri

Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 201918.4.2019 20:05:00 CESTPressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2019 financial results will be released on Thursday, May 2, after the market closes. At 4:30 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the first quarter 2019 and provide a business update. The live webcast of the call can be accessed at the company’s Investors page at http://investors.gilead.com/. Please connect to the company’s website at least 15 minutes prior to the start of the call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 877-359-9508 (U.S.) or 224-357-2393 (international) and dial the conference ID 5259422 to access the call. Telephone replay will be available approximately two hours after the call through 8:00 p.m. Eastern Time, May 4, 2019. To access the replay, please call 855-859-2056 (U.S.) or 404-537-3406 (international) and dial the conference ID

Andersen Global Expands Africa Presence; Signs Collaboration Agreement in Economic Hub of South Africa18.4.2019 13:30:00 CESTPressemelding

Andersen Global is excited to announce the addition of its first collaborating firm in South Africa. Tabacks Attorneys and Corporate Law Advisors, headquartered in Johannesburg, South Africa, has signed a Collaboration Agreement with Andersen Global, an international association of member and collaborating firms. South Africa marks the tenth country in Africa in which Andersen Global has a presence. Led by Chairman David Woodhouse, Tabacks has a team of 27 lawyers who offer legal assistance and commercial advice to a diverse clientele in construction, manufacturing, energy, mining, explosives, retail, hospitality, logistics, pharmaceutical, property and banking industries. The firm is considered a leading law firm in South Africa, and its practice areas include competition law, commercial law, mining, employment law, environmental health & safety law, tax and litigation. “The global economy is rapidly changing, which brings unique challenges to corporate and commercial law,” said David

Amazon and Google Announce Official YouTube Apps to Launch on Fire TV; Prime Video App Coming to Chromecast and Android TV18.4.2019 13:00:00 CESTPressemelding

Today, Amazon (NASDAQ: AMZN) and Google (NASDAQ: GOOGL) announced that in the coming months, the two companies will launch the official YouTube app on Amazon Fire TV devices and Fire TV Edition smart TVs, as well as the Prime Video app for streaming to Chromecast and Chromecast built-in devices. In addition, Prime Video will be broadly available across Android TV device partners, and the YouTube TV and YouTube Kids apps will also come to Fire TV later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005212/en/ “We are excited to work with Amazon to launch the official YouTube apps on Fire TV devices worldwide,” said Heather Rivera, Global Head of Product Partnerships at YouTube. “Bringing our flagship YouTube experience to Amazon Fire TV gives our users even more ways to watch the videos and creators they love.” “We’re excited to bring the Prime Video app to Chromecast and Android TV devices, and to give our c